

Trevi Therapeutics Names Michael Heffernan to its Board of Directors

Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine ER in chronic pruritus conditions

New Haven, CT, March 07, 2017 – [Trevi Therapeutics, Inc.](#) (“Trevi”), a late-stage therapeutics company developing [Nalbuphine® ER](#) for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.

As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors with over 25 years of strong executive, clinical development and commercial experience within the pharmaceutical and healthcare industries. He was previously the Founder, President and CEO of Onset Dermatology, a dermatology-focused company that was spun out of Collegium to create PreCision Dermatology and was later sold to Valeant. Earlier, he was Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp, and later served as President and CEO of PhyMatrix. Mr. Heffernan began his career at Eli Lilly and Company. He is currently the Chairman of Veloxis Pharmaceuticals A/S (OMX: VELO) and serves on the board of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX).

Trevi’s Chairman, Eran Nadav, PhD, said, “Trevi is pleased to be adding another well-respected pharmaceutical executive to the Board. Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate to severe chronic pruritus conditions.”

In addition to Dr. Nadav, Trevi’s Board currently includes Jennifer L. Good, Trevi’s co-founder, President and CEO; W. James O’Shea; and Cayce Denton. Dr. David Meeker is also an Advisor to the Board.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing two conditions for clinical development: prurigo nodularis and uremic pruritus. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of nodules on the skin. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. There are no approved therapies in the US or EU for either condition.

Nalbuphine® ER is an oral extended release opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. Because of Nalbuphine® ER’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials, the Company believes it can have broad utility in treating chronic pruritus.

Founded in 2011, Trevi is headquartered in New Haven, CT.

For additional information, visit www.trevitherapeutics.com.

<https://ir.trevitherapeutics.com/press-releases?item=55>